$ATOS
ATOSSA THERAPEUTICS, INC.

2014 Q2 Form 10-Q Financial Statement

#000114420415046909 Filed on August 06, 2015

View on sec.gov

Income Statement

Concept 2014 Q2
Revenue $9.875K
YoY Change -96.97%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $9.875K
YoY Change -90.5%
Gross Profit Margin 100.0%
Selling, General & Admin $2.686M
YoY Change 7.54%
% of Gross Profit 27196.36%
Research & Development $510.8K
YoY Change 168.89%
% of Gross Profit 5172.32%
Depreciation & Amortization $19.86K
YoY Change -35.23%
% of Gross Profit 201.15%
Operating Expenses $3.196M
YoY Change 18.95%
Operating Profit -$3.187M
YoY Change 23.35%
Interest Expense $1.443K
YoY Change 309.94%
% of Operating Profit
Other Income/Expense, Net -$1.443K
YoY Change
Pretax Income -$3.188M
YoY Change 23.39%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.188M
YoY Change 23.39%
Net Earnings / Revenue -32283.3%
Basic Earnings Per Share
Diluted Earnings Per Share -$22.79M
COMMON SHARES
Basic Shares Outstanding 24.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.30M
YoY Change 495.83%
Cash & Equivalents $14.30M
Short-Term Investments
Other Short-Term Assets $300.0K
YoY Change -86.96%
Inventory $1.910K
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $14.70M
YoY Change 174.5%
LONG-TERM ASSETS
Property, Plant & Equipment $127.7K
YoY Change -37.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $600.0K
YoY Change -86.65%
Total Long-Term Assets $5.119M
YoY Change 8.92%
TOTAL ASSETS
Total Short-Term Assets $14.70M
Total Long-Term Assets $5.119M
Total Assets $19.82M
YoY Change 97.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $790.2K
YoY Change 329.44%
Accrued Expenses $226.6K
YoY Change -85.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.563M
YoY Change -11.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.563M
Total Long-Term Liabilities $0.00
Total Liabilities $1.600M
YoY Change -11.11%
SHAREHOLDERS EQUITY
Retained Earnings -$26.12M
YoY Change 83.18%
Common Stock $24.44K
YoY Change 59.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.26M
YoY Change
Total Liabilities & Shareholders Equity $19.82M
YoY Change 97.11%

Cashflow Statement

Concept 2014 Q2
OPERATING ACTIVITIES
Net Income -$3.188M
YoY Change 23.39%
Depreciation, Depletion And Amortization $19.86K
YoY Change -35.23%
Cash From Operating Activities -$2.260M
YoY Change 7.11%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K
YoY Change 12.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$90.00K
YoY Change 12.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K
YoY Change -98.46%
NET CHANGE
Cash From Operating Activities -2.260M
Cash From Investing Activities -90.00K
Cash From Financing Activities 50.00K
Net Change In Cash -2.300M
YoY Change -316.98%
FREE CASH FLOW
Cash From Operating Activities -$2.260M
Capital Expenditures -$90.00K
Free Cash Flow -$2.170M
YoY Change 6.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Deposit Assets
DepositAssets
25000 USD
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
1854711 USD
CY2015Q2 us-gaap Gross Profit
GrossProfit
839446 USD
CY2015Q2 us-gaap Selling Expense
SellingExpense
732061 USD
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3145326 USD
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3145326 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27686202 shares
CY2014Q2 us-gaap Selling Expense
SellingExpense
223385 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
510458 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2790872 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
4033391 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3193945 USD
us-gaap Sales Revenue Net
SalesRevenueNet
4567425 USD
us-gaap Cost Of Revenue
CostOfRevenue
3062665 USD
us-gaap Selling Expense
SellingExpense
1278915 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6480617 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-6480617 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25805293 shares
us-gaap Selling Expense
SellingExpense
461223 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1307683 USD
us-gaap Operating Expenses
OperatingExpenses
7982581 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6477821 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5964451 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
385740 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-13816 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
32169 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-216477 USD
atos Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-26785 USD
atos Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
8736 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-172836 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1415051 USD
atos Increase Decrease In Product Recall Liabilities
IncreaseDecreaseInProductRecallLiabilities
-199465 USD
atos Increase Decrease In Product Recall Liabilities
IncreaseDecreaseInProductRecallLiabilities
0 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-19027 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-23156 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4858345 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6519316 USD
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
20629 USD
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
66112 USD
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
170441 USD
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
15553 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-191070 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-81665 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13005745 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9503198 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13005745 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9503198 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7956330 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2902217 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6342161 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14298491 USD
us-gaap Profit Loss
ProfitLoss
-5599507 USD
us-gaap Interest Paid
InterestPaid
2192 USD
us-gaap Interest Paid
InterestPaid
3311 USD
us-gaap Profit Loss
ProfitLoss
-6480617 USD
us-gaap Share Based Compensation
ShareBasedCompensation
397715 USD
us-gaap Share Based Compensation
ShareBasedCompensation
385740 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
252924 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
170775 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
64759 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
562694 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-26158 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2276889 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1910 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
61551 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
129719 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-8115 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
542042 USD
atos Noncash Reclass Of Prepaid License Fees
NoncashReclassOfPrepaidLicenseFees
15000 USD
atos Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution
AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution
0 USD
atos Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution
AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution
392711 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
24863 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4454 USD
CY2015Q2 us-gaap Prepaid Advertising
PrepaidAdvertising
0 USD
CY2014Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
50000 USD
CY2015Q2 us-gaap Supplies
Supplies
7499 USD
CY2014Q4 us-gaap Supplies
Supplies
14976 USD
CY2015Q2 us-gaap Prepaid Insurance
PrepaidInsurance
119886 USD
CY2014Q4 us-gaap Prepaid Insurance
PrepaidInsurance
87633 USD
CY2015Q2 us-gaap Deposit Assets
DepositAssets
39821 USD
CY2015Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
39195 USD
CY2014Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
31330 USD
CY2015Q2 atos Prepaid Maintenance And Support Service Fee
PrepaidMaintenanceAndSupportServiceFee
32691 USD
CY2014Q4 atos Prepaid Maintenance And Support Service Fee
PrepaidMaintenanceAndSupportServiceFee
38268 USD
CY2015Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
586100 USD
CY2014Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
522813 USD
CY2015Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
96491 USD
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
93665 USD
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
322385 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
258946 USD
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
682591 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
616478 USD
CY2015Q2 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1630000 USD
CY2014Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1630000 USD
CY2015Q2 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
200000 USD
CY2014Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
200000 USD
CY2015Q2 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
203890 USD
CY2014Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
203038 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
211562 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
112393 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2033890 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2033038 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
107030 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
227130 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
198628 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
169934 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
169015 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
950591 USD
CY2015Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
459592 USD
CY2014Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
752828 USD
CY2015Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
169854 USD
CY2014Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
109653 USD
CY2015Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
210782 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.65
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3675634 shares
CY2014Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
194224 USD
CY2014Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16337 USD
CY2015Q2 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
1502759 USD
CY2014Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
174398 USD
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
279030 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
254126 USD
CY2015Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
118495 USD
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
CY2015Q2 atos Total Shares Authorized
TotalSharesAuthorized
85000000 shares
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 atos Percentage Of Common Stock Outstanding
PercentageOfCommonStockOutstanding
0.020 pure
CY2014Q2 atos Entitled To Receive Worth Of Common Stock
EntitledToReceiveWorthOfCommonStock
30.00
CY2015Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
CY2015Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
11152935 USD
CY2014Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
8250718 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.86
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
39400 USD
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
33255 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.71
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.06
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.89
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
509047 shares
atos Stock Issued During Period Shares Stock Options Exercised1
StockIssuedDuringPeriodSharesStockOptionsExercised1
0 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4312409 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M13D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
344000 USD
atos Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue
63223 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1734948 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3929771 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1145822 shares
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
205112 USD
CY2014Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
167534 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
385740 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
397715 USD
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29046260 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29046260 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24564058 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24564058 shares
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
48619 USD
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1443 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2796 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2049 USD
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
205112 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
385740 USD
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
167534 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
397715 USD
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2577461 shares
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2057210 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y1M28D
atos Noncash Reclass Of Prepaid License Fees
NoncashReclassOfPrepaidLicenseFees
0 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <b><font style="FONT-SIZE: 10pt"></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <b>NOTE 1: NATURE OF OPERATIONS</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Atossa Genetics Inc. (the &#8220;Company&#8221;) was incorporated on April 30, 2009 in the State of Delaware. The Company&#8217;s operations began in December 2008 with the negotiations for the acquisition of the Mammary Aspirate Specimen Cytology Test System, or the MASCT System, patent rights and assignments and the FDA clearance for marketing, which acquisition was completed in January 2009. The Company was formed to develop and market the MASCT System, which is a medical device that collects specimens of nipple aspirate fluid (NAF). The Company&#8217;s fiscal year ends on December 31st.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In December 2011, the Company established The National Reference Laboratory for Breast <font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 48px; LETTER-SPACING: normal; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> Health, Inc., the NRLBH, as</font> a wholly-owned subsidiary which performs the Company&#8217;s NAF cytology test on NAF specimens including those collected with the MASCT System. The NRLBH is certified by College of American Pathologists (CAP) and by Clinical Laboratory Improvement Amendments (CLIA). The current version of the MASCT System is called the ForeCYTE Breast Aspirator. The NRLBH is providing other test services, including the pharmacogenomics test which provides physicians with genetic information that can be used to guide therapeutic decisions and may mitigate the incidence of costly adverse drug reactions and improve efficiencies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company&#8217;s business plan will be successfully executed. The Company&#8217;s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3 us-gaap Other Commitments Description
OtherCommitmentsDescription
On September 1, 2014, the NRLBH entered into a three year agreement with TME Research LLC (TME) which requires TME to provide to the NRLBH 100 tissue specimens in connection with the development of the NextCYTE test. Fees payable to TME under the agreement includes $99,600 up front, $31,500 upon supplying the first 25 specimens and $31,500 at the time of final delivery of all specimens. The agreement is terminable with 60 days prior written notice or immediately upon a material breach.
CY2015Q2 atos Working Capital
WorkingCapital
10300000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <b><font style="FONT-SIZE: 10pt">Use of Estimates:</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13956832 shares
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9643578 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13956832 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9643578 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2693384 shares
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
218539 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
577790 USD
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4116537 USD
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-6533 USD
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2015Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9644423 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
atos Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue
0 USD

Files In Submission

Name View Source Status
0001144204-15-046909-index-headers.html Edgar Link pending
0001144204-15-046909-index.html Edgar Link pending
0001144204-15-046909.txt Edgar Link pending
0001144204-15-046909-xbrl.zip Edgar Link pending
atos-20150630.xml Edgar Link completed
atos-20150630.xsd Edgar Link pending
atos-20150630_cal.xml Edgar Link unprocessable
atos-20150630_def.xml Edgar Link unprocessable
atos-20150630_lab.xml Edgar Link unprocessable
atos-20150630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v416450_10q.htm Edgar Link pending
v416450_ex31-1.htm Edgar Link pending
v416450_ex31-2.htm Edgar Link pending
v416450_ex32-1.htm Edgar Link pending
v416450_ex32-2.htm Edgar Link pending